HB2182 amends Pennsylvania’s Controlled Substance, Drug, Device and Cosmetic Act to expand the state’s drug overdose medication provisions. Specifically, it directs the Department of Health, in its personnel and scope-of-practice rules for emergency medical services, to include administration of an opioid antagonist by prehospital practitioners. The bill expressly names both naloxone and nalmefene as covered opioid antagonists.
The measure is narrowly focused on emergency response to opioid overdoses and would update the legal scope of practice for EMS providers so they may administer either of the listed overdose-reversal medications in prehospital settings. It does not create a new program or penalty structure; rather, it modifies existing law governing overdose medication and EMS practice standards. The bill would take effect 60 days after enactment.
Impact
HB2182 would amend Section 13.8 of the Controlled Substance, Drug, Device and Cosmetic Act and require the Department of Health to revise prehospital practitioner scope-of-practice rules for emergency medical services providers. In practical terms, it would authorize EMS personnel to administer naloxone and nalmefene as opioid antagonists, potentially broadening the tools available for overdose reversal in the field. The bill affects EMS providers, the Department of Health, and patients experiencing opioid overdoses, but it does not otherwise alter controlled substance scheduling or criminal penalties.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the bill appears to be a straightforward public-health measure with an implied supportive posture. Its purpose is consistent with overdose prevention and emergency response efforts, and there is no evidence in the record provided of organized opposition or divided voting. The inclusion of nalmefene alongside naloxone suggests an intent to modernize overdose treatment options rather than to make a controversial policy shift.
Contention
No committee transcript or voting history was provided, so no specific points of contention are documented. If debate occurs, likely issues would center on whether EMS scope-of-practice rules should explicitly include nalmefene in addition to naloxone, how quickly the Department of Health should update regulations, and whether expanding prehospital authority raises training, cost, or implementation concerns. However, none of those concerns are reflected in the materials supplied.